Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients - AIRCo study
- Conditions
- Insulin resistance in colon cancer patientsMedDRA version: 9.1Level: LLTClassification code 10022489Term: Insulin resistance
- Registration Number
- EUCTR2008-007748-33-NL
- Lead Sponsor
- Foreest Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Colon cancer patients scheduled for elective abdominal surgery.
18 to 75 yrs.
Capable of giving informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Diabetes Mellitus
Thyroid medication
Anti-hypertensive medication
Corticosteroids
Diuretics
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method